Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Eur J Pharmacol ; 947: 175625, 2023 May 15.
Article in English | MEDLINE | ID: mdl-36997046

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disorder which affects cognitive functions with negative impact on day to day activities and an ultimate loss of independent living. Current standard of care (SOC) for AD, viz. donepezil, rivastigmine, galantamine, memantine etc. either alone or in combination show modest efficacy without changing the course of the disease. On prolonged treatment, side effects are more common with an eventual loss of efficacy. Aducanumab, a monoclonal antibody is a disease modifying therapeutic agent targeting the toxic amyloid beta (Aß) proteins for its clearance. However, it is found to have only modest efficacy in AD patients and its approval by FDA is controversial. Alternate, effective and safe therapeutics are need of the hour, as AD cases are expected to be doubled by 2050. Recently, 5-HT4 receptors have been envisioned as target for alleviating AD associated cognitive impairment with potential disease modifying ability impacting disease progression. Usmarapride is a 5-HT4 receptor partial agonist, being developed for the possible treatment of AD with symptomatic and disease modifying potential. Usmarapride demonstrated promising effects in ameliorating cognitive deficits in diverse animal models of episodic, working, social, and emotional memories. Usmarapride produced elevation in cortical acetylcholine levels in rats. Furthermore, usmarapride increased levels of soluble amyloid precursor protein alpha, a potential mechanism to reverse toxic Aß peptide pathology. Usmarapride also potentiated the pharmacological effects of donepezil in animal models. To conclude, usmarapride may be a promising intervention for alleviating the cognitive dysfunction in AD patients with disease modifying potential.


Subject(s)
Alzheimer Disease , Rats , Animals , Alzheimer Disease/metabolism , Donepezil/pharmacology , Donepezil/therapeutic use , Serotonin , Amyloid beta-Peptides/metabolism , Rivastigmine/therapeutic use
2.
J Med Chem ; 64(15): 10641-10665, 2021 08 12.
Article in English | MEDLINE | ID: mdl-34251799

ABSTRACT

A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer's disease. Starting from a reported 5-HT4R antagonist, a systematic structure-activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical-pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.


Subject(s)
Alzheimer Disease/drug therapy , Cognition Disorders/drug therapy , Drug Discovery , Neuroprotective Agents/pharmacology , Receptors, Serotonin, 5-HT4/metabolism , Serotonin 5-HT4 Receptor Agonists/pharmacology , Alzheimer Disease/metabolism , Cognition Disorders/metabolism , Dose-Response Relationship, Drug , Humans , Molecular Structure , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , Serotonin 5-HT4 Receptor Agonists/chemical synthesis , Serotonin 5-HT4 Receptor Agonists/chemistry , Structure-Activity Relationship
3.
Proc Natl Acad Sci U S A ; 118(14)2021 04 06.
Article in English | MEDLINE | ID: mdl-33795512

ABSTRACT

Bacteria have evolved a diverse array of signaling pathways that enable them to quickly respond to environmental changes. Understanding how these pathways reflect environmental conditions and produce an orchestrated response is an ongoing challenge. Herein, we present a role for collective modifications of environmental pH carried out by microbial colonies living on a surface. We show that by collectively adjusting the local pH value, Paenibacillus spp., specifically, regulate their swarming motility. Moreover, we show that such pH-dependent regulation can converge with the carbon repression pathway to down-regulate flagellin expression and inhibit swarming in the presence of glucose. Interestingly, our results demonstrate that the observed glucose-dependent swarming repression is not mediated by the glucose molecule per se, as commonly thought to occur in carbon repression pathways, but rather is governed by a decrease in pH due to glucose metabolism. In fact, modification of the environmental pH by neighboring bacterial species could override this glucose-dependent repression and induce swarming of Paenibacillus spp. away from a glucose-rich area. Our results suggest that bacteria can use local pH modulations to reflect nutrient availability and link individual bacterial physiology to macroscale collective behavior.


Subject(s)
Bacterial Physiological Phenomena , Microbial Interactions , Paenibacillus/physiology , Flagellin/metabolism , Hydrogen-Ion Concentration , Proteus mirabilis/physiology , Xanthomonas/physiology
4.
J Med Chem ; 63(6): 2833-2853, 2020 03 26.
Article in English | MEDLINE | ID: mdl-32026697

ABSTRACT

A series of chemical optimizations guided by in vitro affinity at the α4ß2 receptor in combination with selectivity against the α3ß4 receptor, pharmacokinetic evaluation, and in vivo efficacy in a forced swim test resulted in identification of 3-(6-chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane hydrochloride (9h, SUVN-911) as a clinical candidate. Compound 9h is a potent α4ß2 receptor ligand with a Ki value of 1.5 nM. It showed >10 µM binding affinity toward the ganglionic α3ß4 receptor apart from showing selectivity over 70 other targets. It is orally bioavailable and showed good brain penetration in rats. Marked antidepressant activity and dose-dependent receptor occupancy in rats support its potential therapeutic utility in the treatment of depression. It does not affect the locomotor activity at doses several folds higher than its efficacy dose. It is devoid of cardiovascular and gastrointestinal side effects. Successful long-term safety studies in animals and phase-1 evaluation in healthy humans for safety, tolerability, and pharmacokinetics paved the way for its further development.


Subject(s)
Antidepressive Agents/pharmacology , Nicotinic Antagonists/pharmacology , Pyridines/pharmacology , Receptors, Nicotinic/metabolism , Administration, Oral , Animals , Antidepressive Agents/administration & dosage , Antidepressive Agents/chemistry , Bridged Bicyclo Compounds/administration & dosage , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/pharmacology , Depression/drug therapy , Halogenation , Humans , Male , Nicotinic Antagonists/administration & dosage , Nicotinic Antagonists/chemistry , Pyridines/administration & dosage , Pyridines/chemistry , Rats , Rats, Wistar
5.
J Med Chem ; 61(11): 4993-5008, 2018 06 14.
Article in English | MEDLINE | ID: mdl-29763304

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disorder that has a higher prevalence and incidence in people older than 60 years. The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy. Partial agonists of the 5-HT4 receptor (5-HT4R) offer both symptomatic and disease-modifying treatments as they shift amyloid-precursor-protein (APP) processing from the amyloidogenic pathway to the nonamyloidogenic pathway by activating the α-secretase enzyme. In addition, they also offer symptomatic treatment by increasing levels of the neurotransmitter acetylcholine in the brain. Because of this fascinating dual mechanism of action, several chemical scaffolds having 5-HT4R pharmacophores were designed and evaluated. Most of the synthesized compounds showed potent in vitro affinities and in vivo efficacies. Upon analysis of focused structure-activity relationships, compound 4o was identified as a potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy. GR-125487, a selective 5-HT4R antagonist, attenuated the activity of compound 4o in the novel-object-recognition-test cognition model.


Subject(s)
Amides/chemistry , Oxadiazoles/chemistry , Oxadiazoles/pharmacology , Receptors, Serotonin, 5-HT4/metabolism , Serotonin 5-HT4 Receptor Agonists/chemistry , Serotonin 5-HT4 Receptor Agonists/pharmacology , Animals , Chemistry Techniques, Synthetic , Drug Evaluation, Preclinical , Humans , Male , Oxadiazoles/chemical synthesis , Oxadiazoles/pharmacokinetics , Rats , Rats, Wistar , Serotonin 5-HT4 Receptor Agonists/pharmacokinetics , Structure-Activity Relationship
6.
Syst Appl Microbiol ; 39(8): 503-515, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27720237

ABSTRACT

The skin microbiota is import for body protection. Here we present the first comprehensive analysis of the volatile organic compound (VOC) profiles of typical skin-resident corynebacterial and staphylococcal species. The VOC profile of Staphylococcus schleiferi DSMZ 4807 was of particular interest as it is dominated by two compounds, 3-(phenylamino)butan-2-one and 3-(phenylimino)butan-2-one (schleiferon A and B, respectively). Neither of these has previously been reported from natural sources. Schleiferon A and B inhibited the growth of various Gram-positive species and affected two quorum-sensing-dependent phenotypes - prodigiosin accumulation and bioluminescence - of Gram-negative bacteria. Both compounds were found to inhibit the expression of prodigiosin biosynthetic genes and stimulate the expression of prodigiosin regulatory genes pigP and pigS. This study demonstrates that the volatile schleiferons A and B emitted by the skin bacterium S. schleiferi modulate differentially and specifically its interactions with members of diverse bacterial communities. A network of VOC-mediated interspecies interactions and communications must be considered in the establishment of the (skin) microbiome and both compounds are interesting candidates for further investigations to better understand how VOCs emitted by skin bacteria influence and modulate the local microbiota and determine whether they are relevant to antibiotic and anti-virulence therapies.


Subject(s)
Gram-Negative Bacteria/metabolism , Gram-Positive Bacteria/growth & development , Quorum Sensing/drug effects , Skin/microbiology , Volatile Organic Compounds/pharmacology , Acyltransferases/biosynthesis , Corynebacterium/metabolism , Hexosyltransferases/biosynthesis , Humans , Membrane Proteins/biosynthesis , Microbial Sensitivity Tests , Microbiota , Staphylococcus/metabolism , Volatile Organic Compounds/chemistry , Volatile Organic Compounds/isolation & purification
7.
Eur J Med Chem ; 103: 289-301, 2015 Oct 20.
Article in English | MEDLINE | ID: mdl-26363507

ABSTRACT

Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people. The need for improved AD therapies is unmet. The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders associated with AD. Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivatives as 5-HT4R partial agonists. The focused SAR, optimization of ADME properties resulted the discovery of compound 5a as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compound with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.


Subject(s)
Alzheimer Disease/drug therapy , Cognition Disorders/drug therapy , Drug Partial Agonism , Pyridines/chemistry , Pyridines/pharmacology , Receptors, Serotonin, 5-HT4/metabolism , Alzheimer Disease/metabolism , Animals , Cognition Disorders/metabolism , Dogs , Dose-Response Relationship, Drug , Drug Design , Humans , Molecular Structure , Rats , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...